Evotec SE and Sandoz Announce Strategic Partnership Expansion and Potential Sale of Toulouse Site

On July 30, 2025, Evotec SE, a prominent pharmaceutical company specializing in drug discovery solutions across various therapeutic areas, announced a significant development in its strategic partnership with Sandoz AG. The companies have signed a non-binding agreement for the potential sale of the Just – Evotec Biologics EU facility located in Toulouse, France. The transaction is valued at approximately US$ 300 million in cash, with additional considerations related to technology.

Strategic Partnership and Transaction Details

The agreement marks a further evolution of the strategic partnership between Evotec SE and Sandoz AG. The potential sale of the Toulouse site is expected to enhance Sandoz’s capabilities in biologics manufacturing, providing them with access to Evotec’s advanced biologics production facilities. This move aligns with Sandoz’s strategic objectives to expand its biologics portfolio and manufacturing capacity.

Financial Context

As of July 28, 2025, Evotec SE’s share price closed at 7.4 EUR on the Xetra exchange. The company’s market capitalization stands at approximately 1.21 billion EUR. Over the past year, Evotec’s stock has experienced significant volatility, with a 52-week high of 10.62 EUR on November 14, 2024, and a 52-week low of 5.06 EUR on April 6, 2025. The company’s price-to-earnings ratio is currently -5.84, reflecting its ongoing investment in research and development and the inherent risks associated with the pharmaceutical industry.

Market Reaction and Outlook

The announcement has been met with interest from investors and industry analysts, who are closely monitoring the potential impact on Evotec’s financial performance and strategic positioning. The sale of the Toulouse site could provide Evotec with additional capital to invest in its core drug discovery operations and further strengthen its partnerships with pharmaceutical and biotechnology companies worldwide.

As the transaction is subject to further negotiations and regulatory approvals, both companies have emphasized that the agreement is non-binding at this stage. However, the potential sale underscores Evotec’s commitment to optimizing its asset portfolio and enhancing shareholder value.

For more detailed information, stakeholders are encouraged to refer to the official announcements and filings by Evotec SE and Sandoz AG.